Abstract：Objective To explore the clinical effect of Montelukast combined with Budesonide in the treatment of secretory otitis media.Methods A total of 142 patients with secretory otitis media treated in Hu′nan Aerospace Hospital from January 2018 to January 2021 were selected,and they were divided into the control group(71 cases)and the observation group(71 cases)according to the random number table method.The patients in the two groups were given routine treatment,the patients in the control group were treated with Budesonide,and the patients in the observation group were treated with Montelukast on the basis of the control group.The clinical efficacy,tympanic pressure,speech frequency and air conduction hearing threshold of the two groups were observed,and the levels of serum paraoxonase-1(PON1),lipid hydroperoxide(LOOH)and transforming growth factor-β1(TGF-β1),transforming growth factor-β2（TGF-β2),serum interleukin-1β(IL-1β),interleukin-8(IL-8),procalcitonin(PCT)and tumor necrosis factor-α(TNF-α)were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the recurrence rate of the observation group was lower than that of the control group,the differences were statistically significant(P＜0.05).The tympanic pressure and speech frequency air conduction hearing threshold after treatment of the observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).The level of PON1 after treatment of the observation group was higher than that of the control group,and the level of LOOH after treatment of the observation group was lower than that of the control group,the differences were statistically significant(P＜0.05).The levels of TGF-β1 and TGF-β2 after treatment in the observation group were lower than those in the control group,the differences were statistically significant(P＜0.05).The levels of IL-1β,IL-8,PCT and TNF-α after treatment in the observation group were lower than those in the control group,the differences were statistically significant(P＜0.05).Conclusion Montelukast combined with Budesonide in the treatment of secretory otitis media can effectively improve its curative effect,reduce the recurrence rate,improve the symptoms and signs of patients,increase the level of serum PON1 and reduce the level of LOOH,TGF-β1 and TGF-β2,the clinical effect is good,and it is worthy of popularization and application.
Lapointe F，Turcotte S，Véronneau S，et al.Role of protein tyrosine phosphatase epsilon（PTPε）in leukotriene D4-induced CXCL8 expression[J].J Pharmacol Exp Ther，2019，369（2）：270-281.
[14]
Xue DX，Ye LT，Zheng J，et al.Structure based traceless specific fluorescence labeling of smoothened receptor[J].Org Biomol Chem，2019，17（25）：6136-6142.
[15]
Xotlanihua-Gervacio M，Herrera-Moreno JF，Medina-Díaz IM，et al.Relationship between internal and external factors and the activity of PON1[J].Environ Sci Pollut Res Int，2019，26（24）：24946-24957.
[16]
Ahn MS，Eom YW，Oh JE，et al.Transient receptor potential channel TRPV4 mediates TGF-β1-induced differentiation of human ventricular fibroblasts[J].Cardiol J，2020，27（2）：162-170.
京公网安备 11010502046607号